ENT Disorder Treatment Market to Surpass US$ 14,498.96 Mn by 2030

Global ENT Disorder Treatment Market, by Treatment Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type (Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), by Organ Type (Ear, Nose, and Throat), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 11,219.19 Million in 2022 and is expected to exhibit a CAGR of 3.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

The ENT disorders treatment market is expected to gain significant traction with increasing incidence of ENT disorders and increasing environmental pollution globally. According to an article published by Harvard Medical School and Teaching Hospital, 2017, over 360 million people across the globe are suffering from hearing loss.

Global ENT Disorder Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a positive impact on the global ENT disorder treatment market, owing to increase in demand of ENT disorder treatment due to possible association of Covid-19 infection with Otorhinolaryngological Symptoms. For instance, in February 2021, according to data published by National Center for Biotechnology Information, the cross sectional study was performed at SRTR GMC AMBAJOGAI, India, a tertiary care hospital, amongst the patients admitted in COVID 19 isolation ward with a positive RT-PCR report. Amongst the included 180 patients, 112 patients, in 2021 had one or more ENT related symptoms that included throat pain (47.2%), loss of smell (55.5%), loss of taste (58.8%) and hearing loss (54.44%) along with generalized COVID 19 symptoms. ENT symptoms can be considered as biomarkers for early diagnosis of Covid-19 patients ensuring faster treatment and isolation allowing better containment of the disease.

Global ENT Disorder Treatment Market: Key Developments

In October 2021, China Grand Pharmaceutical and Healthcare Holdings Limited (GP (HK)) announced the after the Group submitted the investigational new drug application to the National Medical Products Administration (“NMPA”) for its global innovative drug Ryaltris compound nasal spray in August 2021 and was accepted, and it recently obtained “Notice of Approval for Clinical Trial of Drugs” issued by the National Medical Products Administration (NMPA) which approves the product to conduct Phase III clinical trials for the treatment of allergic rhinitis or rhino conjunctivitis symptoms in patients aged 12 years and above. Ryaltris is a new type of antihistamine and corticosteroids compound nasal spray, and is used to treat severe acute respiratory syndrome (SAR) in adults and adolescents. Each spray of Ryaltris compound nasal spray contains 665μg olopatadine hydrochloride and 25μg mometasone furoate. Three overseas Phase III clinical trials have been completed and the results show that the efficacy of the product is superior to single use of olopatadine hydrochloride or single use of mometasone furoate, and its safety is similar to single use olopatadine hydrochloride or use mometasone furoate alone.

Browse 42 Market Data Tables and 36 Figures spread through 161 Pages and in-depth TOC on “Global ENT Disorder Treatment Market”-  Forecast to 2030, Global ENT Disorder Treatment Market, by Treatment Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type (Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), by Organ Type (Ear, Nose, and Throat), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others),  and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the ENT disorder treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/ent-disorder-treatment-market-1326

Key Takeaways of the Global ENT Disorder Treatment Market:

• The global ENT disorder treatment market is expected to exhibit a CAGR of 3.3% during the forecast period due to the increasing adoption of inorganic growth strategies such as merger and acquisition by the key players in the market for developing and commercialization of novel ENT therapeutics and medical devices. For instance, in December 2017, Entellus Medical, Inc. — a leader in ENT drugs segment — entered a definitive agreement with Stryker Corporation for development of effective ENT solutions through collaboration for developing ENT treatment drugs. Moreover, in July 2017, Entellus Medical acquired Spirox, Inc., a privately held company that manufactures, develops and markets ENT medical devices.
• Among treatment type segment, drug segment holds a dominant position in the global ENT disorder treatment market. This is owing to drug being the first line of treatment in most of the ENT disorders.
• North America is expected to be dominant in the global ENT disorder treatment market over the forecast period. This is attributed to major presence of key players and increasing focus towards enhancing existing treatment options. For instance, in December 2017, Intersect ENT, Inc. — a U.S.-based company — received U.S. FDA approval for Sinuva (mometasone furoate) sinus implant as a treatment option for patients suffering from recurrent nasal polyps. Asia Pacific market is expected to witness a significant growth, owing to increasing awareness among people regarding availability of medical treatments for ENT disorders as well as expansion of key vendors in Asian countries by setting up new manufacturing and distribution facilities. For instance, in October 2017, GlaxoSmithKline — a major pharmaceutical player — opened Asia Headquarters in One-North Singapore.
• Major players operating in the global ENT disorder treatment market include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.